Answers are grounded in this paper and cite their sources.
susceptibility of the two main Omicron variants BA.1 and BA.2 to therapeutic MAbs in advanced clinical development, including eight authorized individual MAbs and three authorized MAb combinations. We estimated the degree to which different MAbs displayed reduced activity against Omicron variants. The marked loss of activity of many MAbs against Omicron variants underscores the importance of developing MAbs that target conserved regions of spike. Highly disparate results between assays indicate the need for improved MAb susceptibility test standardization.
No takes yet. Share an insight, caveat, or question.
Tao et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: